Thank you, Mr. Chair.
I'll make a couple of points, I guess, to start.
The vaccine portfolio includes vaccines across three platforms. I think members know that there are four authorized in Canada: the Moderna, Pfizer, Janssen and AstraZeneca vaccines. Pfizer and Moderna make up the vast majority of deliveries to date.
The other point to make is that there are still vaccine contracts that have yet to deliver. They are still in the works, in terms of stepping through their clinical trials and then going on to production. It's the variety of the portfolio across numerous types of vaccines, but also numerous different suppliers, that is the best mitigation against risk in terms of lack of delivery. There will be bumps, and we've seen them. It's this variety that's important to protect or ensure deliveries for Canadians.
If the member's question is more around the benefit of having various different types of vaccines, from an mRNA to a viral vector to a protein type, I'd have to turn to the Public Health Agency or maybe Dr. Tam.